Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

Summary Background Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin‐13, a key driver of atopic dermatitis (AD). Objectives To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate‐to‐sev...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of dermatology (1951) 2021-03, Vol.184 (3), p.450-463
Hauptverfasser:	Silverberg, J.I., Toth, D., Bieber, T., Alexis, A.F., Elewski, B.E., Pink, A.E., Hijnen, D., Jensen, T.N., Bang, B., Olsen, C.K., Kurbasic, A., Weidinger, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Atopic dermatitis Clinical Trial Corticosteroids Dermatitis Double-blind studies Eczema Immunoglobulin A Immunomodulators Monoclonal antibodies Original Placebos
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!